- Home
- CRBU vs IMA Comparison
CRBU vs IMA Comparison
Compare CRBU & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- IMA
- Stock Information
- Founded
- CRBU 2011
- IMA 2019
- Country
- CRBU United States
- IMA United States
- Employees
- CRBU N/A
- IMA N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBU Health Care
- IMA Health Care
- Exchange
- CRBU Nasdaq
- IMA Nasdaq
- Market Cap
- CRBU 165.8M
- IMA 159.1M
- IPO Year
- CRBU 2021
- IMA N/A
- Fundamental
- Price
- CRBU $1.78
- IMA $8.35
- Analyst Decision
- CRBU Strong Buy
- IMA
- Analyst Count
- CRBU 3
- IMA 0
- Target Price
- CRBU $6.67
- IMA N/A
- AVG Volume (30 Days)
- CRBU 729.3K
- IMA 48.5K
- Earning Date
- CRBU 11-05-2025
- IMA 11-15-2025
- Dividend Yield
- CRBU N/A
- IMA N/A
- EPS Growth
- CRBU N/A
- IMA N/A
- EPS
- CRBU N/A
- IMA N/A
- Revenue
- CRBU $9,121,000.00
- IMA $4,300,000.00
- Revenue This Year
- CRBU $9.23
- IMA N/A
- Revenue Next Year
- CRBU N/A
- IMA N/A
- P/E Ratio
- CRBU N/A
- IMA N/A
- Revenue Growth
- CRBU N/A
- IMA N/A
- 52 Week Low
- CRBU $0.66
- IMA $7.95
- 52 Week High
- CRBU $3.00
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- CRBU 46.16
- IMA N/A
- Support Level
- CRBU $1.72
- IMA N/A
- Resistance Level
- CRBU $1.94
- IMA N/A
- Average True Range (ATR)
- CRBU 0.11
- IMA 0.00
- MACD
- CRBU -0.01
- IMA 0.00
- Stochastic Oscillator
- CRBU 26.53
- IMA 0.00
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.